EUVIMEDEUVIMED entdecken
Crossref

The m6 A modification of CDKN2 A inhibites ferroptosis and affects the resistance of cervical squamous cell carcinoma to cisplatin

Xiang Yong, Xifeng Xu, Xiaoping Zhang, Rui Song, Huaiyuan Hu, Zhen Li, Yanzi Qin

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025

DOI: 10.1007/s00210-025-04246-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Xiang Yong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Wanbei Coal-Electricity Group General Hospital, No. 125, Huaihe West Road, Suzhou City, 234000, Anhui Province, China. Hauptthemen laut MEDLINE: Cisplatin, Ferroptosis, Drug Resistance, Neoplasm, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Science and Technology Innovation Program of Hunan Province, Research Project of the Health Commission of Hunan Province, Science Foundation of Changsha Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical squamous cell carcinoma (CESC) is the fourth most common malignancy and the fourth leading cause of cancer deaths in women worldwide. Despite advances in treatment, cisplatin-based radiotherapy remains the primary treatment option. However, cisplatin resistance is a major challenge, leading to poor prognosis. Therefore, understanding the molecular mechanisms underlying cisplatin resistance is crucial for developing novel therapeutic strategies. Through bioinformatics analysis, we investigated the expression of CDKN2A in the CESC database. WB, IHC, qPCR, and CCK-8 were used for clinical analysis of CDKN2A expression and its correlation with CESC cell proliferation. Through qPCR, CCK-8, ROS, MDA, Fe2+ and WB, we explored how CDKN2A promotes cisplatin resistance by inhibiting ferroptosis. In nude mouse tumor experiments, we investigated how CDKN2A participates in ferroptosis and cisplatin resistance in CESC through the JAK2/STAT3 pathway. Furthermore, we explored CDKN2A as a target of METTL3 and how YTHDF1 enhances the stability of m6A-modified CDKN2A. We investigated the role of CDKN2A in CESC and its involvement in cisplatin resistance. We found that CDKN2A expression was associated with CESC cell ferroptosis and cisplatin resistance. Mechanistically, CDKN2A was identified as a target of METTL3, and YTHDF1 enhanced the stability of m6A-modified CDKN2A. Furthermore, METTL3 inhibited ferroptosis through m6A modification of YTHDF1/CDKN2A, influencing cisplatin resistance in CESC. Our findings provide new insights into the molecular mechanisms of cisplatin resistance in CESC and suggest that targeting the METTL3/YTHDF1/CDKN2A axis may be a promising strategy to overcome this resistance and improve treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinFerroptosisDrug Resistance, NeoplasmUterine Cervical NeoplasmsAntineoplastic AgentsCarcinoma, Squamous CellCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18HumansFemaleAnimalsMice, NudeMiceCell Line, TumorMethyltransferasesCell ProliferationXenograft Model Antitumor AssaysMice, Inbred BALB CAdenosine

Stichwörter der Autor:innen

CDKN2 ACESCCisplatinFerroptosisM6 A RNA methylation

Substanzen

CisplatinAntineoplastic AgentsCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16MethyltransferasesN-methyladenosineMETTL3 protein, humanCyclin-Dependent Kinase Inhibitor p18Adenosine

Autor:innen und Institutionen

  • Department of Pathology, Wanbei Coal-Electricity Group General Hospital, No. 125, Huaihe West Road, Suzhou City, 234000, Anhui Province, China.
  • Suzhou City Key Laboratory of Tumor Pathology, Suzhou City, Anhui Province, China.
  • Department of Pathology, Bengbu Medical University, No. 2600, Donghai Avenue, Bengbu City, Anhui Province, China.
  • Department of Pathology, Wanbei Coal-Electricity Group General Hospital, No. 125, Huaihe West Road, Suzhou City, 234000, Anhui Province, China. huaiyuan_Hu_hhy@163.com.
  • Suzhou City Key Laboratory of Tumor Pathology, Suzhou City, Anhui Province, China. huaiyuan_Hu_hhy@163.com.
  • Department of Pathology, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University/The First Hospital of Changsha, No. 311, Yingpan Road, Kaifu District, Changsha City, 410000, Hunan Provi…

Förderung

  • Science and Technology Innovation Program of Hunan Province
  • Research Project of the Health Commission of Hunan Province
  • Science Foundation of Changsha Science and Technology Project

Zitieren

APA

Yong, X., Xu, X., Zhang, X., Song, R., Hu, H., Li, Z., & Qin, Y. (2025). The m6 A modification of CDKN2 A inhibites ferroptosis and affects the resistance of cervical squamous cell carcinoma to cisplatin. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04246-0

Vancouver

Yong X, Xu X, Zhang X, Song R, Hu H, Li Z, et al. The m6 A modification of CDKN2 A inhibites ferroptosis and affects the resistance of cervical squamous cell carcinoma to cisplatin. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04246-0

BibTeX
@article{Yong2025,
  author = {Yong, Xiang and Xu, Xifeng and Zhang, Xiaoping and Song, Rui and Hu, Huaiyuan and Li, Zhen and Qin, Yanzi},
  title = {The m6 A modification of CDKN2 A inhibites ferroptosis and affects the resistance of cervical squamous cell carcinoma to cisplatin},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  doi = {10.1007/s00210-025-04246-0}
}
Kostenlos starten →